4.7 Review

Developing an effective treatment algorithm for rheumatoid arthritis

Journal

RHEUMATOLOGY
Volume 51, Issue -, Pages V48-V54

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kes122

Keywords

biologic agents; clinical remission; rheumatoid arthritis treatment

Categories

Funding

  1. F. Hoffmann-La Roche Ltd.
  2. Roche
  3. UCB
  4. Abbott
  5. Merck
  6. Pfizer
  7. BMS

Ask authors/readers for more resources

RA is defined by the interrelated triad of disease activity, joint damage and disability. Although disease activity and its associated disability are reversible, joint damage and its associated disability are not. Thus, an important goal of RA therapy is to maximally reduce disease activity and thereby mitigate the accumulation of irreversible joint damage. Treatment for patients with RA should be initiated early and aggressively, with frequent assessments and a goal of achieving remission as quickly as possible after treatment initiation. We propose a treatment algorithm that recommends early and aggressive therapy with high-dose MTX therapy (15-25 mg/week), which may include moderate doses of glucocorticoids. The goal is to achieve low disease activity (determined by a composite measure that includes joint counts) within 3-6 months. If low disease activity is not achieved by 6 months, another conventional DMARD or a biologic agent should be added to the treatment regimen or patients should be switched to another DMARD plus a glucocorticoid. Once low disease activity is achieved, the treatment goal for the ensuing 3-6 months becomes disease remission.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available